Cubist Systematic Strategies LLC Has $234,000 Stake in Schrödinger, Inc. (NASDAQ:SDGR)

Cubist Systematic Strategies LLC lessened its holdings in Schrödinger, Inc. (NASDAQ:SDGR - Free Report) by 79.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,150 shares of the company's stock after selling 48,255 shares during the quarter. Cubist Systematic Strategies LLC's holdings in Schrödinger were worth $234,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Centiva Capital LP bought a new stake in Schrödinger in the fourth quarter valued at $353,000. Brevan Howard Capital Management LP bought a new stake in Schrödinger in the fourth quarter valued at $532,000. Captrust Financial Advisors bought a new stake in Schrödinger in the fourth quarter valued at $240,000. Bayesian Capital Management LP bought a new stake in Schrödinger in the fourth quarter valued at $199,000. Finally, BNP Paribas Financial Markets bought a new stake in Schrödinger in the fourth quarter valued at $330,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on SDGR. Piper Sandler cut their price objective on shares of Schrödinger from $50.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, February 27th. KeyCorp upped their price target on shares of Schrödinger from $30.00 to $32.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Schrödinger currently has a consensus rating of "Buy" and an average price target of $32.80.

Insiders Place Their Bets

In other Schrödinger news, insider Karen Akinsanya sold 16,723 shares of the business's stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $25.09, for a total transaction of $419,580.07. Following the sale, the insider now owns 15,625 shares in the company, valued at approximately $392,031.25. The trade was a 51.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Geoffrey Craig Porges sold 5,491 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $21.76, for a total value of $119,484.16. Following the completion of the transaction, the chief financial officer now owns 27,544 shares in the company, valued at $599,357.44. This represents a 16.62% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 8.60% of the company's stock.

Schrödinger Stock Performance

NASDAQ SDGR traded up $0.18 on Friday, reaching $21.40. The company's stock had a trading volume of 929,810 shares, compared to its average volume of 863,696. Schrödinger, Inc. has a twelve month low of $16.60 and a twelve month high of $28.47. The stock has a market cap of $1.56 billion, a PE ratio of -9.15 and a beta of 1.84. The firm's 50 day moving average is $22.77 and its two-hundred day moving average is $22.09.

Schrödinger (NASDAQ:SDGR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.01). The company had revenue of $59.55 million for the quarter, compared to analyst estimates of $54.60 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. Schrödinger's quarterly revenue was up 62.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.86) EPS. Equities research analysts anticipate that Schrödinger, Inc. will post -2.37 EPS for the current fiscal year.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.